Overview and Scope
Neurodegenerative disorder therapeutics refer to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control.
Sizing and Forecast
The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $18.53 billion in 2023 to $20.04 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to aging population, rising prevalence of neurodegenerative disorders, increasing life expectancy, rising investments from pharmaceutical companies, awareness and advocacy.
The neurodegenerative disorder therapeutics market size is expected to see strongly grown in the next few years. It will grow to $28.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to rising demand for personalized medicine, targeted therapy, increasing availability of clinical trials, rising healthcare expenditure. Major trends in the forecast period include disease-modifying therapies, non-pharmacological interventions, telemedicine and remote monitoring, technological innovations, precision therapeutics, digital health solutions, biomarker-driven trials.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report
Segmentation & Regional Insights
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2023. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=2818&type=smp
Major Driver Impacting Market Growth
Increased prevalence of neurodegenerative among the global population contributes to the growth of the neurodegenerative disorder therapeutics market. The increase in the geriatric population attributes to the increased prevalence of neurodegenerative disorders. According to World Population Prospects, the number of people above 60 years of age will increase to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’™s Association, around 5.8 million Americans are suffering from Alzheimer’™s disease, and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the aging population increases the demand for neurodegenerative disorder therapeutics thereby driving the neurodegenerative disorder therapeutics market.
Key Industry Players
Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca PLC, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
The neurodegenerative disorder therapeutics market report table of contents includes:
1. Executive Summary
2. Neurodegenerative Disorder Therapeutics Market Characteristics
3. Neurodegenerative Disorder Therapeutics Market Trends And Strategies
4. Neurodegenerative Disorder Therapeutics Market – Macro Economic Scenario
5. Global Neurodegenerative Disorder Therapeutics Market Size and Growth
.
.
.
31. Global Neurodegenerative Disorder Therapeutics Market Competitive Benchmarking
32. Global Neurodegenerative Disorder Therapeutics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market
34. Neurodegenerative Disorder Therapeutics Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
